Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.

Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, Mucci LA, Stampfer MJ, Giovannucci E, Loda M.

J Clin Oncol. 2010 Sep 1;28(25):3958-64. doi: 10.1200/JCO.2009.27.0793. Epub 2010 Aug 2.

2.

Association of fatty-acid synthase polymorphisms and expression with outcomes after radical prostatectomy.

Cheng J, Ondracek RP, Mehedint DC, Kasza KA, Xu B, Gill S, Azabdaftari G, Yao S, Morrison CD, Mohler JL, Marshall JR.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):182-9. doi: 10.1038/pcan.2015.11. Epub 2015 Apr 14.

3.

Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival.

Penney KL, Li H, Mucci LA, Loda M, Sesso HD, Stampfer MJ, Ma J.

Prostate. 2013 May;73(7):700-5. doi: 10.1002/pros.22611. Epub 2012 Nov 5.

4.

Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS.

J Clin Oncol. 2008 Dec 10;26(35):5713-20. doi: 10.1200/JCO.2008.18.2675. Epub 2008 Oct 27.

5.

Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study.

Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S.

J Natl Cancer Inst. 2012 Mar 7;104(5):415-20. doi: 10.1093/jnci/djr542. Epub 2012 Feb 6.

6.

Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.

Karyadi DM, Zhao S, He Q, McIntosh L, Wright JL, Ostrander EA, Feng Z, Stanford JL.

Int J Cancer. 2015 May 1;136(9):2166-71. doi: 10.1002/ijc.29241. Epub 2014 Oct 13.

7.

Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk.

Shui IM, Mucci LA, Wilson KM, Kraft P, Penney KL, Stampfer MJ, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):118-26. doi: 10.1158/1055-9965.EPI-12-0670-T. Epub 2012 Nov 2.

8.

A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival.

Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J.

Cancer Prev Res (Phila). 2010 May;3(5):604-10. doi: 10.1158/1940-6207.CAPR-09-0216. Epub 2010 Apr 27.

9.

The Cumulative Effect of Gene-Gene and Gene-Environment Interactions on the Risk of Prostate Cancer in Chinese Men.

Liu M, Shi X, Yang F, Wang J, Xu Y, Wei D, Yang K, Zhang Y, Wang X, Liang S, Chen X, Sun L, Zhu X, Zhao C, Zhu L, Tang L, Zheng C, Yang Z.

Int J Environ Res Public Health. 2016 Jan 27;13(2):162. doi: 10.3390/ijerph13020162.

10.

Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men.

Moreno-Navarrete JM, Botas P, Valdés S, Ortega FJ, Delgado E, Vázquez-Martín A, Bassols J, Pardo G, Ricart W, Menéndez JA, Fernández-Real JM.

Obesity (Silver Spring). 2009 Sep;17(9):1755-61. doi: 10.1038/oby.2009.65. Epub 2009 Mar 19.

11.

Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China.

Zhang GM, Zhu Y, Chen HT, Han CT, Liu F, Xu JF, Ye DW.

Medicine (Baltimore). 2015 Oct;94(42):e1603. doi: 10.1097/MD.0000000000001603.

12.

The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.

Davies NM, Gaunt TR, Lewis SJ, Holly J, Donovan JL, Hamdy FC, Kemp JP, Eeles R, Easton D, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H; PRACTICAL consortium., Lathrop M, Smith GD, Martin RM.

Cancer Causes Control. 2015 Nov;26(11):1603-16. doi: 10.1007/s10552-015-0654-9. Epub 2015 Sep 19.

13.

Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population.

Li Q, Gu C, Zhu Y, Wang M, Yang Y, Wang J, Jin L, Zhu ML, Shi TY, He J, Zhou X, Ye DW, Wei Q.

PLoS One. 2013 Aug 5;8(8):e71968. doi: 10.1371/journal.pone.0071968. Print 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/bc36c048-60e4-48a2-908d-6253e93df062.

14.

Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.

Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Le Marchand L, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J.

J Natl Cancer Inst. 2014 Jun;106(6):dju085. Erratum in: J Natl Cancer Inst. 2014 Jun;106(6):dju194.

15.

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ.

Lancet Oncol. 2008 Nov;9(11):1039-47. doi: 10.1016/S1470-2045(08)70235-3. Epub 2008 Oct 3.

16.

Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P.

Eur Urol. 2014 Jun;65(6):1069-75. doi: 10.1016/j.eururo.2013.12.058. Epub 2014 Jan 4.

17.

Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.

Di Vizio D, Adam RM, Kim J, Kim R, Sotgia F, Williams T, Demichelis F, Solomon KR, Loda M, Rubin MA, Lisanti MP, Freeman MR.

Cell Cycle. 2008 Jul 15;7(14):2257-67. Epub 2008 May 12.

PMID:
18635971
18.

Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.

Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW.

Int J Cancer. 2009 Sep 1;125(5):1143-6. doi: 10.1002/ijc.24423.

19.

[Two single nucleotide polymorphisms on chromosome 3 and the risk of prostate cancer in Chinese men].

Zhou L, Liu M, Huang J, Yang YG, Wei D, Shi XH, Zhang YG, Wang X, Zhou CH, Chen X, Yang Z, Wang JY.

Zhonghua Nan Ke Xue. 2011 Aug;17(8):682-7. Chinese.

PMID:
21898988
20.

Effect of genetic variation in the human fatty acid synthase gene (FASN) on obesity and fat depot-specific mRNA expression.

Schleinitz D, Klöting N, Körner A, Berndt J, Reichenbächer M, Tönjes A, Ruschke K, Böttcher Y, Dietrich K, Enigk B, Filz M, Schön MR, Jenkner J, Kiess W, Stumvoll M, Blüher M, Kovacs P.

Obesity (Silver Spring). 2010 Jun;18(6):1218-25. doi: 10.1038/oby.2009.392. Epub 2009 Oct 29.

Supplemental Content

Support Center